CSIMarket
 
Mersana Therapeutics Inc   (MRSN)
Other Ticker:  
 
 
Price: $5.0400 $0.04 0.699%
Day's High: $5.15 Week Perf: -11.42 %
Day's Low: $ 4.86 30 Day Perf: 32.98 %
Volume (M): 7,277 52 Wk High: $ 9.62
Volume (M$): $ 36,678 52 Wk Avg: $3.31
Open: $4.93 52 Wk Low: $0.80



 Market Capitalization (Millions $) 585
 Shares Outstanding (Millions) 116
 Employees -
 Revenues (TTM) (Millions $) 37
 Net Income (TTM) (Millions $) -172
 Cash Flow (TTM) (Millions $) 46
 Capital Exp. (TTM) (Millions $) 2

Mersana Therapeutics Inc
Mersana Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for the treatment of various types of cancer. Based in Cambridge, Massachusetts, the company's platform technology, called Dolaflexin, uses a proprietary linker and payloads to create targeted therapies that selectively deliver potent anticancer agents to tumors.

Mersana's lead product candidate, XMT-1536, is being developed to address a range of tumor types that express the NaPi2b protein, including ovarian cancer, lung cancer, and cancers of the fallopian tube and peritoneum. XMT-1536 has shown promising results in early-stage clinical trials and has received Fast Track designation from the U.S. Food and Drug Administration.

The company has also established partnerships with pharmaceutical companies, including Takeda and Merck, to collaborate on the development and commercialization of ADC therapies. Mersana Therapeutics aims to transform the treatment landscape for cancer patients by harnessing the potential of ADC technology to deliver targeted and more effective therapies.


   Company Address: 840 Memorial Drive Cambridge 2139 MA
   Company Phone Number: 498-0020   Stock Exchange / Ticker: NASDAQ MRSN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Mersana Therapeutics Inc

Mersana Therapeutics Inc Shows Strong Improvement in Loss Per Share Amid Decline in Revenue

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, has recently released its financial results for the fiscal period ending December 31, 2023. The company reported a significant decrease in loss per share, demonstrating a strong improvement from the prior year. MRSN decreased its loss per share to $-0.14 compared to $-0.35 a year ago, and EPS also improved from $-0.35 per share in the prior reporting period.
However, despite the positive developments in per-share metrics, Mersana Therapeutics saw a decline in revenue for the corresponding reporting period, with a decrease of -27.145% to $10.70 million from $14.69 million in the previous year. Sequentially, revenue surged by 39.01% from $7.70 million.

Clinical Study

Mersana Therapeutics Surges Ahead with Exciting Business Updates, 2024 Milestones, and Participation in Prestigious Healthcare Conference

Published Fri, Jan 5 2024 1:01 PM UTC

Mersana Therapeutics, a renowned clinical-stage biopharmaceutical company, recently released some crucial business updates along with their anticipated milestones for the year 2024. Additionally, the company has announced its participation in the upcoming 42nd Annual J.P. Morgan Healthcare Conference, where they will be presenting their latest advancements in the field of an...

Stock Market Announcement

Mersana Therapeutics, a Cambridge-based biopharmaceutical company, has recently announced the granting of an inducement award to a new employee The award consists of a restricted stock unit (RSU) award, allowing the acquisition of 12,205 shares of the company's common stock This move is in line with Nasdaq Listing Rule 5635(c)(4) and aims to attract and incentivize talented individuals into joining Mersana's workforce

Published Fri, Dec 1 2023 9:30 PM UTC

Mersana Therapeutics, a Cambridge-based biopharmaceutical company, has recently announced the granting of an inducement award to a new employee. The award consists of a restricted stock unit (RSU) award, allowing the acquisition of 12,205 shares of the company's common stock. This move is in line with Nasdaq Listing Rule 5635(c)(4) and aims to attract and incentivize talente...

Mersana Therapeutics Inc

Mersana Therapeutics Inc's Strong Performance in Q3 2023 Shows Promising Growth Potential

Mersana Therapeutics Inc, a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) targeting cancers, recently reported its financial results for the third quarter of 2023. The company saw a decrease in its loss per share compared to the previous year, along with an improvement in its income per share from the previous reporting period.
During the third quarter of 2023, Mersana Therapeutics Inc reported a loss per share of $-0.35, a decrease from $-0.61 per share in the same period the year before. Additionally, the company's income per share improved from $-0.47 per share in the previous reporting period. These figures indicate positive momentum for Mersana Therapeutics Inc and suggest potential growth in the company's profitability.

Mersana Therapeutics Inc

Mersana Therapeutics Inc Shrinks Loss in Q2, Elevating Pharmaceutical Standings



The stock market is constantly evolving, with investors eagerly tracking the earnings of various companies. Mersana Therapeutics Inc, a major player in the pharmaceutical preparations sector, has recently released its second-quarter earnings report for 2023. The company's performance during this period has shown significant improvement compared to the previous year, revealing positive advancement in both revenue and income per share.
Highlights of the Report:
During the second quarter of 2023, Mersana Therapeutics Inc demonstrated a notable decrease in its loss per share. The company reported a loss of $-0.47 per share, a marked improvement from the $-0.55 per share loss recorded during the same period in the previous year. This indicates the company's efforts to streamline operations and enhance profitability.






 

Mersana Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Mersana Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Mersana Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com